Center for Experimental Research and Medical Studies, A.O.U. San Giovanni Battista, Torino, Italy.
PLoS One. 2010 Nov 30;5(11):e14167. doi: 10.1371/journal.pone.0014167.
Phenylketonuria (PKU) is a rare inborn error of metabolism often complicated by a progressive bone impairment of uncertain etiology, as documented by both ionizing and non- ionizing techniques.
Peripheral blood mononuclear cell (PBMC) cultures were performed to study osteoclastogenesis, in the presence or absence of recombinant human monocyte-colony stimulating factor (M-CSF) and receptor activator of NFκB ligand (RANKL). Flow cytometry was utilized to analyze osteoclast precursors (OCPs) and T cell phenotype. Tumour necrosis factor α (TNF-α), RANKL and osteoprotegerin (OPG) were quantified in cell culture supernatants by ELISA. The effects of RANKFc and anti-TNF-α antibodies were also investigated to determine their ability to inhibit osteoclastogenesis. In addition, bone conditions and phenylalanine levels in PKU patients were clinically evaluated.
Several in vitro studies in PKU patients' cells identified a potential mechanism of bone formation inhibition commonly associated with this disorder. First, PKU patients disclosed an increased osteoclastogenesis compared to healthy controls, both in unstimulated and M-CSF/RANKL stimulated PBMC cultures. OCPs and the measured RANKL/OPG ratio were higher in PKU patients compared to healthy controls. The addition of specific antagonist RANKFc caused osteoclastogenesis inhibition, whereas anti-TNF-α failed to have this effect. Among PBMCs isolated from PKU patients, activated T cells, expressing CD69, CD25 and RANKL were identified. Confirmatory in vivo studies support this proposed model. These in vivo studies included the analysis of osteoclastogenesis in PKU patients, which demonstrated an inverse relation to bone condition assessed by phalangeal Quantitative Ultrasound (QUS). This was also directly related to non-compliance to therapeutic diet reflected by hyperphenylalaninemia.
Our results indicate that PKU spontaneous osteoclastogenesis depends on the circulating OCP increase and the activation of T cells. Osteoclastogenesis correlates with clinical parameters, suggesting its value as a diagnostic tool for an early assessment of an increased bone resorption in PKU patients.
苯丙酮尿症(PKU)是一种罕见的代谢性遗传病,常伴有病因不明的进行性骨损伤,这一点已被离子和非离子技术所证实。
进行外周血单核细胞(PBMC)培养,以研究破骨细胞生成,分别在存在和不存在重组人单核细胞集落刺激因子(M-CSF)和核因子κB 配体受体激活剂(RANKL)的情况下进行。利用流式细胞术分析破骨细胞前体(OCP)和 T 细胞表型。通过 ELISA 定量检测细胞培养上清液中的肿瘤坏死因子α(TNF-α)、RANKL 和骨保护素(OPG)。还研究了 RANKFc 和抗 TNF-α 抗体的作用,以确定它们抑制破骨细胞生成的能力。此外,还对 PKU 患者的骨状况和苯丙氨酸水平进行了临床评估。
在 PKU 患者的细胞中进行的几项体外研究确定了一种与该疾病相关的骨形成抑制的潜在机制。首先,与健康对照组相比,PKU 患者在未受刺激和 M-CSF/RANKL 刺激的 PBMC 培养物中均显示出破骨细胞生成增加。与健康对照组相比,PKU 患者的 OCP 和测量的 RANKL/OPG 比值更高。添加特异性拮抗剂 RANKFc 可抑制破骨细胞生成,而抗 TNF-α 则没有这种作用。在从 PKU 患者中分离的 PBMC 中,鉴定出表达 CD69、CD25 和 RANKL 的活化 T 细胞。体内研究证实了这一模型。这些体内研究包括对 PKU 患者破骨细胞生成的分析,结果表明其与通过指尖定量超声(QUS)评估的骨状况呈负相关。这也与高苯丙氨酸血症反映的治疗饮食不依从性直接相关。
我们的结果表明,PKU 自发的破骨细胞生成依赖于循环 OCP 的增加和 T 细胞的激活。破骨细胞生成与临床参数相关,表明其作为评估 PKU 患者骨吸收增加的早期诊断工具的价值。